Homocystein: Metabolism and role in different pathologies;L'homocystéine, métabolisme et implication dans le développement de diverses pathologies

Cahiers de Nutrition et de Dietetique

Volumn 37, Issue 4, 2002, Pages 251-259

  Guilland, J C ^a,d   Favier, A ^b   Potier De Courcy, Geneviève ^c   Galan, Pilar ^c   Hercberg, S ^c  

^a Laboratoire de Physiologie   (France)

^b UFR de Pharmacie   (France)

^c INSERM   (France)

^d HÔPITAL DU BOCAGE   (France)

Author keywords

Genes; Homocysteine; Pathologies; Vitamins

Indexed keywords

CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; METHIONINE; PYRIDOXINE;

AMINO ACID METABOLISM; CARDIOVASCULAR DISEASE; COGNITIVE DEFECT; COLORECTAL CANCER; GENE; GENETIC POLYMORPHISM; HUMAN; HYPERHOMOCYSTEINEMIA; NEURAL TUBE DEFECT; NUTRIENT; REVIEW;

EID: 17744406922     PISSN: 00079960     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Brattström L., Wilcken D.E.- Homocysteine and cardiovascular disease: cause or effect? Am. J. Clin. Nutr., 2000, 72, 315-323.
2. Van der Put N.M., Blom H.J. - Neural tube defects and a disturbed folate dependent homocysteine metabolism. Eur. J. Obstet. Gynecol. Reprod Biol., 2000, 92, 57-61.
3. Reed T., Malinow M.R., Christian J.C., Upson B. - Estimates of heritability of plasma homocyst(e) ine levels in aging adult male twins. Clin. Genet., 1991, 39, 425-428.
4. Genest J.J.Jr., Mc Namara J.R., Upson B. et al. - Prevalence of familial hyperhomocyst(e) inemia in men with premature coronary artery disease. Arterioscler Thromb., 1991, 11, 1129-1136.
5. Chango A., Potier de Courcy G., Boisson F. et al. - 5,10-methylenetetrahydrofolate reductase common mutations, folate status and plasma homocysteine in healthy French adults of the Supplementation in Vitamins and Minerals Antioxidant (SUVIMAX) cohort. Br. J. Nutr., 2000, 84, 891-896.
6. Jacques F., Bostom A.G., Williams R.R. et al. - Relation between folate status, a common mutation in methylene-tetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation, 1996, 93, 7-9.
7. Van der Mooren M.J., Wouters M.G., Blom H.J., Schellekens L.A., Eskes T.K., Rolland R. - Hormone replacement therapy may reduce high serum homocysteine in postmenopausal women. Eur. J. Clin. Invest., 1994, 24, 733-736.
8. Wouters M.G.A.J., Moorres M.T.E.C., van der Mooren M.J. et al. - Plasma homocysteine and menopausal status. Eur. J. Clin. Invest., 1995, 25, 801-805.
9. Aubard Y., Darodes N., Cantaloube M. - Hyperhomocysteinemia and pregnancy - Review of our present understanding and therapeutic implications. Eur. J. Obstet. Gynecol. Reprod. Biol., 2000, 93, 157-165.
10. Ubbink J.B. - Vitamin nutrition status and homocysteine: an atherogenic risk factor. Nutr. Rev., 1994, 52, 383-387.
11. Cravo M.L., Gloria L.M., Selhub J. et al. - Hyperhomocysteinemia in chronic alcoholism: correlation with folate, vitamin B-12, and vitamin B-6 status. Am. J. Clin. Nutr., 1996, 63, 220-224.
12. Kang S.S., Wong P.W., Norusis M. - Homocysteinemia due to folate deficiency. Metabolism, 1987, 36, 458-462.
13. Brattstrom L., Israelsson B., Norrving B. et al. - Impaired homocysteine metabolism in early-onset cerebral and peripheral occlusive arterial disease. Effects of pyridoxine and folic acid treatment. Atherosclerosis, 1990, 81, 51-60.
14. Jacob R.A., Wu M.M., Henning S.M., Swendseid M.E. - Homocysteine increases as folate decreases in plasma of healthy men during short-term dietary folate and methyl group restriction. J. Nutr., 1994, 124, 1072-1080.
15. Selhub J., Jacques P.F., Wilson P.W., Rush D., Rosenberg I.H. - Vitamin status and intake as primary determinants of homocysteinemia in an elderly population (see comments). J. Am. Med. Assoc., 1993, 270, 2693-2698.
16. Savage D.G., Lindenbaum J., Stabler S.P., Allen R.H. - Sensitivity of serum methylmalonic acid and total homocysteine determinations for diagnosing cobalamin and folate deficiences. Am. J. Med., 1994, 96, 239-246.
17. Essama-Tjani J.C., Guilland J.C., Potier de Courcy G., Fuchs F., Lombard M., Richard D. - Folate status worsens in recently institutionalized elderly people without evidence of functional deterioration. J. Am. Coll. Nutr., 2000, 19, 392-404.
18. 12 serum folate, and red cell folate levels in relation to plasma homocysteine: is a preventable public health issue on the rise? Clin. Biochem., 2000, 33, 337-343.
19. Homocysteine lowering Trialists' collaboration. - Lowering blood homocystein with folic acid based supplements: meta-analysis of randomised trials. B.M.J., 1998, 316, 894-898.
20. 12. Am. J. Cardiol., 1999, 83, 821-825.
21. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register, 1996, 61, 8791-8797.
22. 9 (acide folique). In: Apports nutritionnels conseillés pour la population franćaise. (A. Martin ed.) Tec-Doc, Lavoisier, 2001.
23. Stampfer M.J., Malinow M.R., Willett W.C. et al. - A prospective study of plasma homocyst(e) ine and risk of myocardial infarction in US physicians. J.A.M.A, 1992, 268, 877-881.
24. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A. G - A quatitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake [see comments]. J. Am. Med. Assoc., 1995, 274, 1049-1057.
25. Voutilainen S., Lakka T.A., Hamelahti P., Lehtimaki T., Poulsen H.E., Salonen J.T. - Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J. Intern. Med., 2000, 248, 217-222.
26. Folsom A.R., Nieto F.J., McGovern P.G. et al. - Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation, 1998, 98, 204-210.
27. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. - Homocyst(e) ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler. Thromb. Vasc. Biol., 1997, 17, 1947-1953.
28. Brattström L., Wilcken D.E., Ohrvik J., Burdin L. - Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease: the result of a meta-analysis. Circulation, 1998, 98, 2520-2526.
29. Kluitjjmans L.A.J., Kastelein J.J.H., Lindemans J. et al. - Thermolabile methylenetatrahydrofolate reductase in coronary artery disease. Circulation, 1997, 96, 2573-2577.
30. Verhoef P., Rimm E.B., Hunter D.J. et al. - A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. J. Am. Coll. Cardiol., 1998, 32, 353-359.
31. Brattström L. - Common mutation in the methylenetetrahydrofolate reductase gene offers no support for mild hyperhomocysteinemia being a causal risk factor for cardiovascular disease. Circulation, 1997, 96, 3805-3807.
32. Rees M.M., Rodgers G.M. - Homocysteinemia: Association of a metabolic disorder with vascular disease and thrombosis. Thromb. Res., 1993, 71, 337-359.
33. Bienvenu T., Ankri A., Chadefaux B., Montalescot G., Kamoun P. - Elevated total plasma homocysteine, a risk factor for thrombosis. Relation to coagulation and fibrinolytic parameters. Thromb. Res., 1993, 70, 123-129.
34. Fermo I., Vignano d'Angelo S., Paroni R., Mazzola G., Calori G., d'Angelo A. - Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann. Intern. Med., 1995, 123, 747-753.
35. Malinow M.R., Kang S.S., Taylor L.M. et al. - Prevalence of hyperhomocyst(e) inemia in patients with peripheral arterial occlusive disease. Circulation, 1989, 79, 1180-1188.
36. Den Heijer M., Koster T., Blom H.J. et al. - Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med., 1996, 334, 759-762.
37. Falcon C.R., Cattaneo M., Panzeri D., Martinelli I., Mannucci P.M. - High prevalence of hyperhomocyst(e) inemia in patients with juvenile venous thrombosis. Arterioscler. Thromb., 1994, 14, 1080-1083.
38. Amundsen T., Ueland P.M., Waage A. - Plasma homocysteine levels in patients with deep veinous thrombosis. Arterioscler. Thromb. Vasc. Biol., 1995, 15, 1321-1323.
39. Simioni P., Prandoni P., Burlma A. et al. - Hyperhomocysteinemia and deep-vein thrombosis. Thromb. Haemost., 1996, 76, 883-886.
40. Den Heijer M., Blom H.J., Gerrits W.B.J., Rosendaal F.R., Haak H.L., Wijermans P.W. - Is hyperhomocysteinemia a risk factor for recurrent venous thrombosis? Lancet, 1995, 345, 882-885.
41. Den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B.J., Bos G.M. - Hyperhomocysteinemia and venous thrombosis: A meta-analysis. Thromb. Haemost., 1998, 80, 874-877.
42. Wilcken D.E.L., Dudman N.P. - Mechanism of thrombogenesis and accelerated atherogenesis in homocysteinemia. Haemostasis, 1989, 19 (suppl. 1), 14-23.
43. Dudman N.P., Wilcken D.E., Stocker R. - Circulating lipid hydroperoxide levels in human hyperhomocysteinemia. Relevance to development of arteriosclerosis. Arterioscler. Thromb., 1993, 13, 512-516.
44. Von Eckardstein A., Malinow M.R., Upson B et al. - Effects of age, lipoproteins and hemostatic parameters on the role of homocysteinemia as a cardiovascular risk factor in men. Arterioscler. Thromb., 1994, 14, 460-464.
45. Durand P., Lussier-Cacon S., Blache D. - Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEB J, 1997, 11, 1157-1168.
46. Werler M.M., Shapiro S., Mitchell A.A. - Periconceptional folic acid exposure and risk of occurent neural tube defects. J. Am. Med. Assoc., 1993, 269, 1257-1261.
47. Daly L.E., Kirke P.N., Molloy P.A., Weir D.G., Scott J.M. - Folate levels and neural tube defects. Implications for prevention. J. Am. Med. Assoc., 1995, 274, 1698-1702.
48. Czeizel A.E., Dudas I. - Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N. Engl. J. Med., 1992, 327, 1832-1835.
49. Bower C., Stanley F.J. - Periconceptional vitamin supplementation and neural tube defects; evidence from a case-control study in Western Australia and a review of recent publications. J. Epidemiol. Community Health, 1992, 46, 157-161.
50. Mulinare J., Cordero J.F., Erickson J.B., Berry R.J. - Periconceptional use of multivitamins and the occurrence of neural tube defects. J. Am. Med Assoc., 1988, 260, 3141-3145.
51. Shaw G.M., Lammer E.J., Wasserman C.R., O'Malley C.D., Tolarova M.M. - Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionnally. Lancet, 1995, 346, 393-396.
52. Steegers-Theunissen R.P., Boers G.H., Trijbels F.J. et al. - Maternal hyperhomocysteinemia: a risk factor for neural tube defects? Metabolism, 1994, 43, 1475-1480
53. Essien F.B. - Maternal methionine supplementation promotes the remediation of axial defects in Ascd mouse neural tube mutants. Teratology, 1992, 45, 205-212.
54. Kang S.S., Wong P.W., Susmano A., Sora J., Norusis M., Ruggie N. - Thermolabile methylenetatrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am. J. Hum. Genet., 1991, 48, 536-545.
55. Haworth J.C., Dilling L.A., Surtees R.A. et al. - Symptomatic and asymptomatic methylenetetrahydrofolate reductase deficiency in two adult brothers. Am. J. Med. Genet., 1993, 45, 572-576.
56. Watanabe M., Osada J., Aratani Y. et al. - Mice deficient in cystathionine beta-synthase: animal models for mild and severe hyperhomocyst(e) inemia. Proc. Natl. Acad. Sci., 1995, 92, 1585-1589.
57. Van der Put N.M., Steegers-Theunissen R.P., Frosst P. et al. - Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet, 1995, 346, 1070-1071.
58. James S.J., Pogribna M., Pogribny I. P et al. - Abnormal folate metabolism and mutation in the methylenetatrahydrofolate reductase gene may be maternal risk factors for Down syndrome. Am. J. Clin. Nutr., 1999, 70, 495-501.
59. Hobbs C.A., Sherman S.L., Yi P. et al. - Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome Am. J. Human Genet., 2000, 67, 623-630.
60. Ray J.G., Laskin C.A. - Folic acid and homocyst(e) ine metabolic defects and the risk of placental abruption, pre-eclampsia and spontaneous pregnancy loss: a systematic review. Placenta, 1999, 20, 519-529.
61. Kaiser T., Brennecke S.P., Moses E.K. - Methylenetetrahydrofolate reductase polymorphisms are not a risk factor for pre-eclampsia, eclampsia in Australian women. Gynecol. Obstet. Invest., 2000, 50, 100-102.
62. Bell I.R., Edman J.S., Selhub J. et al. - Plasma homocysteine in vascular disease and non-vascular dementia of depressed elderly people. Acta. Psychiatr. Scand., 1992, 86, 386-390.
63. 12 and folate deficiency more frequent in elderly patients with Alzheimer's disease? J. Gerontol., 1997, 52, M76-79.
64. McCaddon A., Hudson P., Davies G., Hughes A., Williams J., Wilkinson C. - Homocysteine and cognitive decline in healthy elderly. Dement. Geriatr. Cogn. Disord., 2001, 12, 309-313.
65. Riggs K.M., Spiro III A., Tucker K., Rush D. - Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive peformance in the Normative Aging Study. Am. J. Clin. Nutr., 1996, 63, 306-314.
66. Lehmann M., Gottfries C.G., Regland B. - Identification of cognitive impairment in the elderly: homocysteine is an early marker. Dement. Geriatr. Cogn. Disord., 1999, 10, 12-20.
67. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch. Neurol., 1998, 55, 1449-1455.
68. Kalmijn S., Launer L., Lindenmans J., Bots M.L., Hofman A., Breteler M.M. - Total homocysteine and cognitive decline in a community-based sample of elderly subjects. The Rotterdam Study. Am. J. Epidemiol., 1999, 150, 283-289.
69. Lipton S.A., Kim W.-K., Choi Y.-B. et al. - Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D aspartate receptor. Proc. Natl Acad. Sci. US, 1997, 94, 5923-5928.
70. Fassbender K., Mielke O., Bertsch T., Nafe B., Froschen S., Hennerici M. - Homocysteine in cerebral macroangiography and microangiopathy. Lancet, 1999, 353, 1586-1587.
71. Bostom A.G., Culleton B.F. - Hyperhomocysteinemia in chronic renal disease. J. Am. Soc. Nephrol., 1999, 10, 891-900.
72. Fodinger M., Horl W.H., Sunder-Plassmann G. - Molecular biology of 5,10-methylenetetrahydrofolate reductase. J. Nephrol., 2000, 13, 20-33.
73. Kim Y.-I - Folate and carcinogenesis: evidence, mechanisms and implications. J. Nutr. Biochem., 1999, 10, 66-88.
74. Slattery M.L., Potter J.D., Samowitz W., Schaffer D., Leppert M. - Methylenetetrahydrofolate reductase, diet, and risk of colon cancer. Cancer Epidemiol. Biomarkers Prev., 1999, 8, 513-518.
75. Ulrich C.M., Kampman E., Bigler J. et al. - Colorectal adenomas and the C677T MTHFR polymorphism: evidence for gene-environment interaction? Cancer Epidemiol. Biomarkers Prev., 1999, 8, 659-668.
76. Ulvik A., Evensen E.T., Lien E.A. et al. - Smoking, folate and methylenetatrahydrofolate reductase status as interactive determinants of adenomatous and hyperplastic polyps of colorectum. Am. J. Med. Genet., 2001, 101, 246-254.
77. Kim Y.-I. - Methylenetetrahydrofolate reductase polymorphisms, folate and cancer risk: a paradigm of genenutrient interactions in carcinogenesis. Nutr. Rev., 2000, 58, 205-209.
78. Chen J, Giovannucci E.L., Hunter D.J. - MTHFR polymorphism, methyl-replete diets and the risk of colorectal carcinoma and adenoma among US men and women: an example of gene-environment interactions in colorectal tumorigenesis. J. Nutr., 1999, 129, 560S-564S.